Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $18.42 and last traded at $18.56, with a volume of 109,432 shares trading hands. The stock had previously closed at $18.82.

Several analysts recently issued reports on the stock. Credit Suisse Group AG assumed coverage on shares of Intellia Therapeutics in a report on Tuesday, May 31st. They issued an “outperform” rating and a $39.00 price target on the stock. Leerink Swann assumed coverage on shares of Intellia Therapeutics in a report on Tuesday, May 31st. They issued a “market perform” rating and a $32.00 price target on the stock. Wedbush assumed coverage on shares of Intellia Therapeutics in a report on Tuesday, May 31st. They issued an “outperform” rating and a $38.00 price target on the stock. Finally, Jefferies Group assumed coverage on shares of Intellia Therapeutics in a report on Tuesday, May 31st. They issued a “hold” rating and a $33.00 price target on the stock.

The firm’s market capitalization is $637.13 million. The firm’s 50 day moving average is $24.67 and its 200-day moving average is $25.11.

In related news, Director Carl L. Gordon purchased 250,000 shares of the stock in a transaction on Wednesday, May 11th. The shares were bought at an average price of $18.00 per share, for a total transaction of $4,500,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Institutes For Biomed Novartis purchased 277,777 shares of the stock in a transaction on Wednesday, May 11th. The shares were bought at an average price of $18.00 per share, for a total transaction of $4,999,986.00. The disclosure for this purchase can be found here.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.